Browse by author
Lookup NU author(s): Professor Nicola PaveseORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2026 American Neurological Association. The Parkinson's Progression Markers Initiative (PPMI) has remained at the vanguard of Parkinson's disease (PD) research through evolving recruitment strategies that mirror advances in PD biology. PPMI was initially focused on untreated, early-stage PD. Over time, it has expanded to include genetic cohorts, prodromal participants identified via olfactory testing and risk factor questionnaires targeting people with rapid eye movement (REM) sleep behavior disorder (RBD). Most recently, PPMI has focused on the biology underlying PD and sought to recruit individuals defined by neuronal alpha-synuclein disease (NSD) biomarkers. This evolution from clinical to biological enrollment demonstrates the feasibility of biomarker-driven cohort design and establishes a scalable model for early detection and prevention research in neurodegenerative disease. ANN NEUROL 2026.
Author(s): Siderowf A, Heathers LEA, Fabrizio K, Kuhl MM, Kopil CM, Flagg E, McMahon BA, Coffey CS, Bright A, Totten M, Lemon LP, Bryan E, Prakash N, Pavese N, Bloem BR, Alcalay RN, Mirelman A, Stefanis L, Okubadejo N, Tolosa E, Tanner CM, Simuni T, Chowdhury S, Tropea TF, Marek K, Foroud T
Publication type: Editorial
Publication status: Published
Journal: Annals of Neurology
Year: 2026
Pages: Epub ahead of print
Online publication date: 10/05/2026
Acceptance date: 01/04/2026
ISSN (print): 0364-5134
ISSN (electronic): 1531-8249
Publisher: John Wiley and Sons Inc.
URL: https://doi.org/10.1002/ana.78239
DOI: 10.1002/ana.78239
PubMed id: 42108682
